In August 2023, CVS Health announced that it would begin offering several adalimumab biosimilars at a low wholesale acquisition cost (WAC) through the CVS Caremark commercial template formularies. This would also include a low-WAC adalimumab product from its subsidiary Cordavis. The program was instituted in April 2024, while also excluding branded Humira® from coverage. The strategy … Continue reading A Conversation With Joshua Fredell, PharmD, Vice President, PBM & Specialty Product Development, CVS Health